FDA Approved: SAPHNELO — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for SAPHNELO (anifrolumab-fnia) from AstraZeneca Pharmaceuticals LP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

SUPPL AP for SAPHNELO (ANIFROLUMAB-FNIA)